Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to -$5.8 million.

  • Day One Biopharmaceuticals' Cash from Operations fell 11143.77% to -$5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$119.6 million, marking a year-over-year decrease of 3368.35%. This contributed to the annual value of -$78.1 million for FY2024, which is 4680.87% up from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Cash from Operations stood at -$5.8 million for Q3 2025, which was down 11143.77% from -$24.8 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' Cash from Operations peaked at $50.8 million during Q3 2024, and registered a low of -$59.0 million during Q1 2025.
  • For the 4-year period, Day One Biopharmaceuticals' Cash from Operations averaged around -$28.3 million, with its median value being -$30.0 million (2024).
  • Its Cash from Operations has fluctuated over the past 5 years, first soared by 23693.34% in 2024, then tumbled by 11143.77% in 2025.
  • Over the past 4 years, Day One Biopharmaceuticals' Cash from Operations (Quarter) stood at -$35.3 million in 2022, then dropped by 17.17% to -$41.4 million in 2023, then increased by 27.47% to -$30.0 million in 2024, then soared by 80.66% to -$5.8 million in 2025.
  • Its Cash from Operations stands at -$5.8 million for Q3 2025, versus -$24.8 million for Q2 2025 and -$59.0 million for Q1 2025.